Appendix 3 SASB Index Table

Code	Accounting Metric	Referenced Chapter / Disclosure	Corresponding SDGs	Page number
Topic: Safety of Clinical Trial Participants				
HC-BP-210a.1	Discussion, by world region, of management process for ensuring quality and patient safety during clinical trials	**1.3 R&D of innovative biopharmaceuticals** The risk assessment for clinical trials is monitoring by a CRO, and the internal standard operating procedure "Vendor Selection and Management" is the main requirement for performing quality assurance and quality management activities in clinical trials. There are no cases of clinical trials discontinued with CROs due to GCP violations. At each stage of clinical development, we have an audit and inspection mechanism and comply with the "Declaration of Helsinki" and the "International Council for the Regulation of Pharmaceuticals Good Clinical Practice (ICH-GCP)." Written informed consent shall be obtained from the subjects before the clinical trials are officially launched, and strictly screening suitable subjects according to the inclusion and exclusion criteria of the investigational new drug (IND) application.		40
HC-BP-210a.2	Number of FDA Sponsor Inspections related to clinical trial management and pharmacovigilance that resulted in: (1) Voluntary Action Indicated (VAI) and (2) Official Action Indicated (OAI)	No such information is available currently.		
HC-BP-210a.3	Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing countries	No such information is available currently.		
Topic: Access to Medicines				
HC-BP-240a.1	Description of actions and initiatives to promote access to health care products for priority diseases and in priority countries as defined by the Access to Medicine Index	**1.5 Global Commercialization Strategy** **Ch6 Access to Healthcare and Medicine Pricing** One of the Company's 4 focused disease areas is Hematologic diseases. As of the issuance of this report, the drug BESREMi® for the treatment of PV has been sold in 30 countries around the world. We are also sponsoring the MPN Asia for 5 consecutive years since 2016. Also the conference of MPN/MDS/AML, MPN Research Foundation, Physicians Education Resource, PV Reporter and other relative activies since 2021, that physicians and scholars around the world who are concerned about MPN disease can continue to have access to the latest research and treatment modalities. The subsections of Chapter 6 of this report, describe in detail of our Access to Medicine strategy, implementation plan and annual results, and future goals following the Access to Medicine Index.		42 121 125 127 133
HC-BP-240a.2	List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP)	No such drug is available since November 2021, when BESREMi® is launched in the U.S. market.		
Topic: Affordability & Pricing				
HC-BP-240b.1	Number of settlements of Abbreviated New Drug Application (ANDA) litigation that involved payments and/or provisions to delay bringing an authorized generic product to market for a defined time period	No such information is available since November 2021, when BESREMi® is launched in the U.S. market.		

Code	Accounting Metric	Referenced Chapter / Disclosure	Corresponding SDGs	Page number
HC-BP-240b.2	Percentage change in: (1) average list price and (2) average net price across U.S. product portfolio compared to previous year	No such information is available since November 2021, when BESREMi® is launched in the U.S. market.		
HC-BP-240b.3	Percentage change in: (1) list price and (2) net price of product with largest increase compared to previous year	**6.4 Stable and Safe High-Quality Drugs** The Company's pricing strategy is to formulate reasonable and fair prices based on the affordability of medical expenses in various countries with reference to the "WHO Guideline on Country Pharmaceutical Pricing Policies" issued by the World Health Organization (WHO). The price in 2021 is the sam as 2020. In the future, we will continue to track the price of drugs around the world to ensure patient affordability.		134
Topic: Drug Safety				
HC-BP-250a.1	List of products listed in the Food and Drug Administration's (FDA) MedWatch Safety Alerts for Human Medical Products database	**3.6 Effective pharmacovigilance and recall mechanism** The Company has completed the establishment of a pharmacovigilance mechanism at the headquarter, and the subsidiaries and other drug supplying countries or regions will complete the establishment in accordance with local regulations and drug marketing schedules. We will continue to monitor the safety and risk management of new drugs after they are launched. There are six serious adverse drug reaction (ADR) events since BESREMi® is released in the U.S. market. We collected the detials in the PSUR report and continuously tracked.	 	73 83
HC-BP-250a.2	Number of fatalities associated with products as reported in the FDA Adverse Event Reporting System			73 83
HC-BP-250a.3	Number of recalls issued; total units recalled			73,83
HC-BP-250a.4	Total amount of product accepted for takeback, reuse, or disposal			73,83
HC-BP-250a.5	Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practalsoices (cGMP), by type			73 83
Topic: Counterfeit Drugs				
HC-BP-260a.1	Description of methods and technologies used to maintain traceability of products throughout the supply chain and prevent counterfeiting	**3.1 Constructing a comprehensive supply chain system** **3.6 Effective pharmacovigilance and recall mechanism** We have established records of serial number, batch number and factory activities for each batch of pharmaceutical products to ensure batch flow and traceabilityto managed and tracked them with standard operating procedures such as the "Product Code and Batch Number Coding Procedures." We have also formulated "Product Secondary Packaging and Serialization Batch Record" to regulate the operation process of commercial packaging and serialization of products by overseas outsourced processing plants. BESREMi®, which is expected to be launchedin the U.S. market, has also completed the introduction of drug serialization in 2020.		65 85
HC-BP-260a.2	Discussion of process for alerting customers and business partners of potential or known risks associated with counterfeit products	**3.6 Effective pharmacovigilance and recall mechanism** When a drug is reported to have a known or probable manufacturing defect, deterioration, counterfeit or any other serious quality problem, our QA department will initiate an investigation and initiate product recall procedures and recovery actions. Furthermore, according to the hazard level of drugs, we remove the drugs from the user-end within a certain period, properly dispose of the recovered product, and notify the local competent authority.		85
HC-BP-260a.3	Number of actions that led to raids, seizure, arrests, and/or filing of criminal charges related to counterfeit products	No such information is availablesince November 2021, when BESREMi® is launched in the U.S. market.		

Code	Accounting Metric	Referenced Chapter / Disclosure	Corresponding SDGs	Page number
Topic: Ethical Marketing				
HC-BP-270a.1	Total amount of monetary losses as a result of legal proceedings associated with false marketing claims	No such information is available in the Company.		
HC-BP-270a.2	Description of code of ethics governing promotion of off-label use of products	**2.2 Compliance and Business Ethics** In terms of marketing and labeling, we strictly follow the ethical standards of the WHO and other countries in the pharmaceutical industry. To ensure that our pharmaceutical employees interact with healthcare professionals in a reasonable manner and in accordance with relevant pharmaceutical and medical regulations, employees have received internal training and legal education on the ethical standards of pharmaceutical marketing.		58
Topic: Employee Recruitment, Developing & Retention				
HC-BP-330a.1	Discussion of talent recruitment and retention efforts for scientists and research and development personnel	**4.1 A happy workplace** The Company creates a stable working environment for retaining talents through compensation and benefits, friendly environment, humane management, smooth internal rotation and training and development. We are recruiting biomedical and R&D talents in various professional fields, and actively recruiting clinical and global management professionals.		91
HC-BP-330a.2	(1) Voluntary and (2) involuntary turnover rate for: (a) executives/senior managers, (b) midlevel managers, (c) professionals, and (d) all others	**4.1 A happy workplace** The retention rate for executive positions in 2021 was 89.36%, and the growth rate of all PEC's employees has continued to grow steadily over the past three years.		91
Topic: Supply Chain Management				
HC-BP-430a.1	Percentage of (1) entity's facilities and (2) Tier I suppliers' facilities participating in the Rx-360 International Pharmaceutical Supply Chain Consortium audit program or equivalent third-party audit programs for integrity of supply chain and ingredients	**3.2 Accountable Supplier Management** The Company has conducted external audits of our upstream supply chain. and stringent internal procedures to monitor the selection, evaluation, and approval of suppliers of raw materials, materials, and instruments/equipment. We also conduct supplier/contractor evaluations on a regular basis each year, using a combination of internal evaluation reviews and on-site audits. For 3 consecutive years, 100% of internal assessments and field audits were completed.		69 72
Topic: Business Ethics				
	Total amount of monetary losses as a result of legal proceedings associated with corruption and bribery	No such information is available in PEC and no related fees or charges.		
HC-BP-510a.2	Description of code of ethics governing interactions with health care professionals			
Activity Metrics				
HC-BP-000.A	Number of patients treated	**1.5 Global Commercialization Strategy** As of Q42021, BESREMi® is sold in 30 countries around the world and used by clincal trials, "Compassionate Use" and marketing channels nearly 1500 patients.		42
HC-BP-000.B	Number of drugs (1) in portfolio and (2) in research and development (Phases 1-3)	**1.3 R&D of innovative biopharmaceuticals** **6.2 Innovative medicine - solving unmet medical needs** Please refer to the product pipeline and clinical trial information on the company's official website.		39 125